TB-500 (and full T4) has a more developed preclinical cardiac evidence base than BPC-157, particularly in post-myocardial-infarction remodelling models, supported in part by NIH-funded investigation
Key safety principles include: Never share syringes, needles, or vials with another person Always use a new, sterile syringe for each injection Maintain strict hand hygiene and site cleaning protocols Store and dispose of sharps according to local regulations Don't inject into areas with visible infection, inflammation, rashes, or moles Contact your physician if you notice signs of infection at an injection site (increasing redness, warmth, swelling, or discharge) AOD-9604 itself has a well-established safety profile at therapeutic doses
Please do not submit medical records, diagnoses, dosing questions, treatment histories, government identification, or other sensitive information unless we specifically request information for a lawful verification purpose
Common risks include unknown purity, inconsistent concentration, contamination, bad storage, sketchy supply chains, and misleading labels
At ChiroHer, we are committed to providing personalized care
document )
